# Digoxin for Congenital Erythrocytosis Due to Up-Regulated Hypoxia Sensing

> **NCT03433833** · PHASE1 · WITHDRAWN · sponsor: **University of Illinois at Chicago**

## Conditions studied

- Polycythemia; Familial
- Erythrocytosis; Familial
- VHL Gene Mutation
- HIF-2alpha Erythrocytosis
- PHD2 Erythrocytosis
- Chuvash Erythrocytosis

## Interventions

- **DRUG:** Digoxin

## Key facts

- **NCT ID:** NCT03433833
- **Lead sponsor:** University of Illinois at Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-11-10
- **Primary completion:** 2024-04-16
- **Final completion:** 2024-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study Not Funded
- **Last updated:** 2024-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03433833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03433833, "Digoxin for Congenital Erythrocytosis Due to Up-Regulated Hypoxia Sensing". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03433833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*